1. Home
  2. TDF vs OABI Comparison

TDF vs OABI Comparison

Compare TDF & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Dragon Fund Inc.

TDF

Templeton Dragon Fund Inc.

N/A

Current Price

$10.21

Market Cap

268.9M

Sector

Finance

ML Signal

N/A

Logo OmniAb Inc.

OABI

OmniAb Inc.

N/A

Current Price

$4.38

Market Cap

294.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TDF
OABI
Founded
1994
2012
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.9M
294.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TDF
OABI
Price
$10.21
$4.38
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
39.3K
1.7M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.56
EPS
N/A
N/A
Revenue
N/A
$18,666,000.00
Revenue This Year
N/A
$52.42
Revenue Next Year
N/A
$64.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.26
$1.32
52 Week High
$12.20
$5.43

Technical Indicators

Market Signals
Indicator
TDF
OABI
Relative Strength Index (RSI) 30.55 57.57
Support Level N/A $1.90
Resistance Level $11.14 $5.43
Average True Range (ATR) 0.19 0.31
MACD -0.05 -0.10
Stochastic Oscillator 7.79 29.87

Price Performance

Historical Comparison
TDF
OABI

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: